Aytu Biopharma (AYTU) Retained Earnings (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Retained Earnings data on file, last reported at -$347.8 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 10.86% year-over-year to -$347.8 million in Q1 2026; TTM through Mar 2026 was -$347.8 million, a 10.86% decrease from a year earlier, with the FY2025 full-year figure at -$333.5 million, down 4.24% from the prior year.
• Retained Earnings for Q1 2026 stood at -$347.8 million, down from $356.4 million in the prior quarter.
• Over the last five years, Retained Earnings for AYTU reached as high as $356.4 million in Q4 2025 and fell as low as -$347.8 million in Q1 2026.
• Historically, Retained Earnings has averaged -$271.3 million across 5 years, with a median of -$312.5 million in 2023.
• Across the five-year window, Retained Earnings slumped 61.01% in 2022 and surged 212.16% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$294.5 million in 2022, then retreated by 6.12% to -$312.5 million in 2023, then declined by 1.67% to -$317.7 million in 2024, then jumped by 212.16% to $356.4 million in 2025, then slumped by 197.59% to -$347.8 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$347.8 million in Q1 2026, $356.4 million in Q4 2025, and -$331.6 million in Q3 2025.